Proteins

Product Data Sheet

BF-168

Cat. No.: HY-112830 CAS No.: 634911-47-0 Molecular Formula: $C_{18}H_{17}FN_{2}O_{2}$ Molecular Weight: 312.34 Target: Amyloid-β

Pathway: **Neuronal Signaling**

Storage: Powder -20°C 3 years

> 4°C 2 years

F	NH
---	----

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (160.08 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.2016 mL	16.0082 mL	32.0164 mL
	5 mM	0.6403 mL	3.2016 mL	6.4033 mL
	10 mM	0.3202 mL	1.6008 mL	3.2016 mL

Please refer to the solubility information to select the appropriate solvent.

- В	$\boldsymbol{\alpha}$	$\mathbf{I} \cap$	\sim 1	$\sim \Lambda$		CTI\	//
- 61			C II		1 A		/ I I V

Description	BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K_i of 6.4 nM for A β 1-42.
IC ₅₀ & Target	Ki: 6.4 nM (Aβ1-42) ^[1] .
In Vitro	BF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in AD brain. BF-168 is a candidate probe for PET and is found to specifically recognize both neuritic and diffuse plaques, with a K_i of 6.4 nM for A β 1-42 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Intravenous injection of BF-168 in PS1/APP and APP23 transgenic mice result in specific in vivo labeling to both compact and diffuse amyloid deposits in the brain. In addition, ¹⁸ F-radiolabeled BF-168 demonstrates abundant initial brain uptake (3.9% injected dose/gm at 2 min after injection) and fast clearance (t _{1/2} =24.7 min) after intravenous administration in normal mice. Furthermore, autoradiograms of brain sections from APP23 transgenic mice at 180 min after intravenous injection of [¹⁸ F]BF-168 shows selective labeling of brain amyloid deposits with little nonspecific binding ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

^{*} The compound is unstable in solutions, freshly prepared is recommended.

. Okamura N, et al. Styrylbe	nzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004 Mar 10;24(10):2535-41.
	Caution: Product has not been fully validated for medical applications. For research use only.
	Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
	Address. 1 Deer rain Di, Saite Q, Mollinoath Sahetion, NS 80052, 85/1

Page 2 of 2 www.MedChemExpress.com